Industry-leading behavioral science tool SPUR™ is validated to predict adherence and will be offered through the Clinical ink technology platform
Clinical ink, a global life science technology company, announces the promotion of John Pappadakis from EVP, Global Business Development to Chief Commercial Officer and Megan Petrylak from EVP, Clinical Operations to Chief Operating Officer.
Clinical ink announces EDCXtra: An integrated web-based EDC, DDC and eCOA platform.
Clinical ink announces EDCXtra™ : An integrated web-based EDC, DDC and eCOA platform Read More...
Clinical ink announced the appointment of Dr. Nicholas Alp as Chief Medical Officer will lead the creation of innovative solutions and commercial strategies for clinical trial technology based on his experience as an interventional cardiologist and clinical trialist.
Clinical ink Appoints Dr. Nicholas Alp, MD PhD as Chief Medical Officer Read More...
Clinical ink announces an integrated suite of eClinical tools for cardiometabolic clinical trials.
Clinical ink announces GlucoseReady™ Read More...
Clinical ink is expanding its patient engagement suite with the inclusion of the SPUR™ behavioral diagnostic tool created by Observia.
Clinical ink Expands Patient Engagement Solutions with Behavioral Diagnostic Tool SPUR™ Read More...
Clinical ink is setting a new industry benchmark in advancing study build timelines. Harnessing the power of the latest eCOA technology, Clinical ink can now reduce study build timelines to as little as 10 days.
Clinical ink, a global life science technology company, announces the appointment of Jeff Bock, Vice President of Data Management and Tom Haag, Vice President of Data Quality Control.
Clinical ink announced the appointment of Andrew Kraus as Chief Technology Officer who will lead the development of the company’s expanding technology portfolio to support clinical trials.
Clinical ink Appoints Andrew Kraus as Chief Technology Officer Read More...
Clinical ink is delighted to announce its partnership with Teckro, a trailblazer in site user engagement and clinical trial technology solutions.
Clinical ink and Teckro Partner to Enhance Site User Engagement Read More...
Clinical ink announces the publication of “Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study” in npj Parkinson’s Disease.
Clinical ink now offers continuous glucose monitoring (CGM) within its integrated digital biomarker solution.
Clinical ink Announces New Continuous Glucose Monitoring Solution Read More...
Sales and Solutions
Direct 1.336.464.0697
Support
Toll-Free 1.800.301.5033
Direct 1.336.464.0697
Insert HTML text here.
Request more information, submit questions, set up a demonstration, and more.
